The idea that US interest rates will stay higher for longer is probably wrong 
Lawsuit Against Goldman Sachs, Morgan Stanley Over Archegos Collapse Dismissed by US Judge 
Orbital resonance − the striking gravitational dance done by planets with aligning orbits 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
How the UK’s new rights around flexible working will affect employees and businesses 
Tesla Cybertruck Recall: NHTSA Flags 3,878 Units for Pedal Issue 
Why the government’s haste in changing the health system could come back to haunt it 
What is minoxidil, the anti-balding hair growth treatment? Here’s what the science says 
Digital trade protocol for Africa: why it matters, what’s in it and what’s still missing 
The rising flood of space junk is a risk to us on Earth – and governments are on the hook 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
TSMC to Hike Prices for Chips Made Outside Taiwan, Impacting Global Device Costs 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
